Why the study?
There is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, particularly for congestion, and appropriate diuretic titration strategies remain unclear.
What is the role of carbohydrate antigen 125 (CA125) as a prognostic biomarker and guide for decongestion therapy in patients with heart failure?
Design
Review
Authors
Loading...
Highlights need for affordable congestion biomarkers beyond NPs in HF; leaves open optimal diuretic strategies pending RCTs.
What is the role of carbohydrate antigen 125 (CA125) as a prognostic biomarker and guide for decongestion therapy in patients with heart failure?
This review highlights the emerging role of CA125 as a cost-effective biomarker for prognosis and guiding diuretic therapy in heart failure.
Kumrić et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: